SOLID ORAL DOSAGE FORM COMPRISING POMALIDOMIDE
MX434099BActive Publication Date: 2026-05-19TECNIMEDE SOCIEDADE TECNICO MEDICINAL SA
Patent Information
- Authority / Receiving Office
- MX · MX
- Patent Type
- Patents
- Current Assignee / Owner
- TECNIMEDE SOCIEDADE TECNICO MEDICINAL SA
- Filing Date
- 2022-10-14
- Publication Date
- 2026-05-19
AI Technical Summary
Technical Problem
Pomalidomide, a class IV compound with low aqueous solubility, poses challenges in developing pharmaceutical compositions due to slow dissolution rates, affecting bioavailability and stability, particularly in oral formulations.
Method used
A new pharmaceutical dosage form comprising pomalidomide with anhydrous lactose, hypromellose, and specific excipients like croscarmellose sodium and magnesium stearate, optimized for immediate release, ensuring high dose dissolution within 60 minutes and stability under various conditions.
Benefits of technology
The formulation achieves consistent and rapid drug release, maintaining stability and bioavailability, as demonstrated by favorable dissolution profiles and stability tests under accelerated and long-term conditions.
✦ Generated by Eureka AI based on patent content.
Abstract
This description relates to the formulation of new pharmaceutical dosage forms of pomalidomide for therapeutic use. The new pharmaceutical dosage form is an immediate-release pharmaceutical composition comprising pomalidomide.
Need to check novelty before this filing date? Find Prior Art